Bach joining Delfi as CMO; plus Gritstone, Draupnir, Veralox, Cytovia, Avisa and more
Peter Bach joined Baltimore-based liquid biopsy company Delfi Diagnostics Inc. as CMO. Bach, who is director of Memorial Sloan Kettering Cancer Center’s Center for Health Policy and Outcomes, is a physician, epidemiologist and researcher who has written extensively on the cost and value of cancer drugs. He also served as senior adviser for cancer policy to CMS in 2005-06.
Roman Yelensky is stepping down as EVP and CTO of Gritstone bio Inc. (NASDAQ:GRTS) to co-found and lead an undisclosed cancer diagnostics start-up. Separately, the immunotherapy company hired Celia Economides, the former SVP of strategy and external affairs at Kezar Life Sciences Inc. (NASDAQ:KZR), as EVP and CFO. Economides succeeds Jean-Marc Bellemin, who left Gritstone in December to join Iovance Biotherapeutics Inc. (NASDAQ:IOVA)...